Lesine (Drospirenone, Ethinylestradiol)

The combination works by suppressing the mid‑cycle surge of luteinizing hormone, thereby inhibiting ovulation. Drospirenone also provides progestogenic activity that thickens cervical mucus, making it hostile to sperm, while ethinylestradiol stabilizes the endometrial lining, reducing breakthrough bleeding.

The dosage regimen of Lesine is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule and any variations are set by the prescriber based on individual patient needs.

Lesine is classified as pregnancy category X, meaning it must not be used during pregnancy because it can harm the fetus. While limited data exist for breastfeeding, combined oral contraceptives are generally considered compatible with lactation; however, a clinician should evaluate the risk‑benefit profile for each mother.

To place an order, submit an enquiry on the Lesine product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Lesine contains drospirenone, a progestogen with anti‑mineralocorticoid activity, which may reduce water retention compared with older progestins. Its estrogen component, ethinylestradiol, is standard across many combined pills. Clinicians may choose Lesine for patients who desire a lower risk of bloating or who need a specific hormonal profile, while efficacy in preventing pregnancy remains comparable.

Lesine tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or bottle to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Lesine is taken orally, usually once each day at the same time, with or without food. Patients should swallow the tablet whole and continue the daily regimen for the prescribed cycle, typically 21 active tablets followed by a hormone‑free interval, unless directed otherwise by their healthcare provider.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, especially in women who smoke, are over 35, or have pre‑existing risk factors. Other severe concerns are severe allergic reactions and liver disease; patients should be monitored closely for any signs of these conditions.

Lesine is contraindicated in women who are pregnant or breastfeeding, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or known hypersensitivity to drospirenone, ethinylestradiol or any tablet components. Additionally, smokers over 35 years of age should avoid using combined oral contraceptives due to heightened cardiovascular risk.